Background and Aims: Vedolizumab [VDZ], a humanized monoclonal antibody targeting α4β7 integrin, is effective in induction and maintenance therapy in patients with inflammatory bowel disease [IBD] who have not adequately responded to standard therapies, and high vedolizumab trough levels [VTLs] Conclusions: Undetectable sMAdCAM-1 appears strongly associated with clinical remission during VDZ maintenance therapy. Combination of undetectable sMAdCAM-1 with high VTL is also potentially interesting for therapeutic drug monitoring. Baseline RA concentrations are predictive of clinical remission. These findings need to be confirmed in further prospective studies.
Introduction
In recent decades, biologic therapies such as anti-tumor necrosis factor [TNF] and vedolizumab [VDZ] have been developed for treating patients with inflammatory bowel disease [IBD] . [1] [2] [3] [4] To optimize their use, therapeutic drug monitoring [TDM] has emerged as an interesting approach. Performances of TDM have been so far assessed with anti-TNF agents, and several decision trees based on trough levels of anti-TNF and anti-drug antibodies have been proposed. [5] [6] [7] VDZ is a humanized monoclonal antibody targeting α4β7 integrin. It modulates inflammation of the gastrointestinal wall by limiting lymphocyte homing to the lamina propria without inducing systemic immunosuppression. Vedolizumab was approved in 2014 for induction and maintenance therapy in IBD patients who had not adequately responded to one or more standard therapies [corticosteroids, immunomodulators, or anti-TNF].
We recently reported the association between low VDZ trough levels [VTLs] during induction therapy and the need for additional doses within 6 months. 8 Other recent studies have reported the association of high VTLs with clinical remission. [9] [10] [11] [12] However, other factors may be involved in the clearance of the drug and in clinical outcomes. To the best of our knowledge, none of these factors has been studied so far. Some authors evaluated the integrin α4β7 expression on multiple lymphocyte subsets before and during VDZ therapy, but the method used [flow cytometry] appears hardly applicable in clinical practice. 12 Leukocyte recruitment is pivotal for the initiation and perpetuation of IBD and is controlled by the interactions of chemokines and adhesion molecules. Mucosal addressin cell adhesion molecule 1 [MAdCAM-1] is a cell-surface immunoglobulin superfamily member that promotes the adhesion of T and B cells to vascular endothelium and is critical for lymphocyte homing to the gut. 13 Its expression is increased in patients with IBD and in animal colitis models. 14, 15 In a recent placebo-controlled trial evaluating an anti-MAdCAM-1 antibody, Vermeire et al. reported a correlation between the circulating soluble form of MAdCAM-1 [sMAdCAM-1] and its tissue expression. 16 Vitamin A is the term given to a collection of related molecules known as retinoic acid [RA] . 17 During vitamin A metabolism, the irreversible conversion of retinal to RA is catalyzed by retinaldehyde dehydrogenase [RALDH] , which is expressed by dendritic cells [DCs] from Peyer patches and mesenteric lymph nodes. 18 The RALDH allows intestinal DCs to convert retinal to RA, which in turn induces the expression of the gut homing receptor α4β7 on T cells. [18] [19] [20] Upregulation of α4β7 by RA on the surface of B cells has also been demonstrated. 21 Polymorphism in the CYP26B1 enzyme is likely involved in the degradation of RA and has been described in patients with Crohn's disease [CD] , supporting the role of vitamin A in the pathophysiology of CD. 22 In this study, we retrospectively examined the relationships between sMAdCAM-1 and RA concentrations during the response to VDZ in IBD patients. We hypothesized that patients with high levels of circulating RA could be potential good responders to VDZ, because RA induces the lymphocyte expression of α4β7, which is the target of VDZ. In contrast, in the presence of high levels of sMAd-CAM-1, the α4β7 integrin expressed at the lymphocyte surface could be overloaded with sMAdCAM-1, reducing the accessibility of the integrin to VDZ, and this could therefore be associated with a lack of response to VDZ.
Methods

Patients
All consecutive IBD patients from three referral centers who were treated with VDZ as maintenance therapy and in clinical remission after induction therapy were retrospectively included in the present study. They had failed or had developed intolerance to at least one line of anti-TNF.
Three hundred milligrams of VDZ were administered at Weeks [W] 0, 2, and 6 as induction therapy, and then were administered once every 8 weeks during the maintenance therapy. Serum samples during the induction phase were not collected. At W10, clinical activity was assessed, and patients in whom clinical remission was not achieved received an additional dose of 300 mg VDZ at W10 followed by an infusion of VDZ once every 4 weeks as optimization of the treatment during the maintenance therapy.
Clinical activity was assessed at W10 in all patients, at W30 in patients in remission, at W14 in optimized patients and in patients who relapsed before W30 (using the Harvey-Bradshaw index [HBI] and faecal calprotectin [fCal] in patients with CD, and the Mayo score in patients with ulcerative colitis [UC]). Clinical remission was defined as a HBI of ≤3 with fCal levels of <250 µg/g stools for CD, and as a Mayo score of ≤3 with an endoscopic subscore of 0 to 1 for UC without concomitant corticosteroids. Primary non-response to VDZ at W14 and relapse were defined by a HBI of >4 with fCal of >250 µg/g stools for CD, and by a Mayo score of >4 with an endoscopic subscore of >1 for UC. Patients with primary non-response to VDZ at W14 in spite of VDZ infusion at W10 were excluded from our study, which focused on maintenance therapy.
A medical visit was performed before each VDZ infusion. In all patients, sMAdCAM-1 and RA concentrations were measured in the blood before the first VDZ infusion. In patients in clinical remission, measurements of VTL, sMAdCAM-1, and RA concentrations were performed at W30. For patients in clinical relapse after W10, measurements of VTL, sMAdCAM-1, and RA concentrations were performed at the time of relapse. Measurements of VDZ, sMAdCAM-1, and RA concentrations were performed retrospectively. Hence, the management of patients was independent of these results. All patients signed an informed written consent to the protocol, which was approved by the Ethics Committee of Saint-Etienne University and Centre National Informatique et Liberté [CNIL 1849323 v 0].
Measurements of vedolizumab, soluble MAdCAM-1, and retinoic acid concentrations
Human sMAdCAM-1 concentrations were measured using the HycultBiotech ELISA assay [Clinisciences, Montrouge, France]. Briefly, the human sMAdCAM-1 ELISA is a ready to use solid-phase sandwich ELISA that allows the determination of sMAdCAM-1 concentrations between 0.41 and 100 ng/mL. We tested the spike of VDZ at a range of between 1 and 30 µg/ml in a V0 sample with a high concentration of sMAdCAM-1 [<5%]. We did not observe any significant differences in sMAdCAM-1 with or without VDZ. Moreover, the situation was exactly the same when dosing withVDZ in the presence of sMAdCAM-1. Again, we did not observe any interference in VDZ measurement in the presence of sMAdCAM-1, as in the V0 samples. Human RA concentrations were measured with the CUSABIO competitive inhibition ELISA assay [Clinisciences, Montrouge, France]. The detection range of this assay is from 0.42 to 10 ng/mL. Vedolizumab and anti-VDZ antibodies were measured using the Lisa-Tracker duo VDZ ELISA assay [Theradiag, Marnela-Vallée, France]. The assay ranges from 2 to 60 µg/mL for VDZ and from 35 to 500 ng/mL for anti-VDZ antibodies. We used in this study a drug-sensitive ELISA assay for monitoring anti-VDZ antibodies. This assay has been designed to reduce the formation of complexes between VDZ and anti-VDZ antibodies by using specific buffers. However, with the drug-sensitive ELISA technique, when VDZ is detectable in the serum, the value of the anti-VDZ antibody is considered 'inconclusive'.
Statistical analysis
The primary objective was to evaluate the sMAdCAM-1 and RA concentration, in addition to the VTL, and to assess clinical remission under VDZ maintenance therapy. First, a cross-sectional analysis was carried out including only measurements of sMAdCAM-1, RA, and VTL [performed during maintenance therapy at W30 or at the time of relapse]. Linear correlations between VDZ, sMAdCAM-1, or RA concentrations were assessed using the Pearson correlation coefficient. The most associated threshold with clinical remission for each biological variable were identified by receiver operating characteristic [ROC] curves. Factors associated with clinical remission were then identified using uni-and multivariate logistic regressions, including dichotomized variables defined by previously identified thresholds. Variables that achieved a p < 0.1 value on univariate analysis were included in the multivariate analysis. Pharmacokinetic profiles combining dichotomized values significantly associated with clinical remission on multivariate analysis were then tested according to proportions of patients in remission or relapse, and were compared with the Chi 2 or Fisher tests, as appropriate. Similar analyses focusing on quartiles of the biomarkers were also performed. The one-sided Cochrane-Armitage trend test was used to compare quartiles.
Second, in a longitudinal analysis, the median concentrations of sMAdCAM-1 and RA before and during VDZ maintenance therapy were compared using the paired Mann-Whitney test. Predictive performances for clinical remission of these biomarkers (sensitivity, specificity, accuracy, positive predictive value [PPV], and negative predictive value [NPV]) were tested by ROC curves. Statistical analysis was performed using IBM SPSS 20.0.0 [IBM, Somers, NY]. The significance level was defined as p ≤ 0.05.
Results
Cross-sectional analysis
Characteristics of the population study are reported in Table 1 Figure 1 ]. Sampling was performed at the time of relapse in patients who relapsed and was therefore not at trough time in all the 24 patients. Sampling was not performed during the induction phase. However, in these cases, sampling was performed at least 4 weeks after the last infusion. Conversely, sampling was performed 8 The optimal thresholds of biomarkers associated with clinical remission with their diagnostic performances were determined by ROC curves and reported in 
Longitudinal analysis
Discussion
For the first time, we showed that undetectable sMAdCAM-1 concentrations during maintenance therapy were strongly associated with clinical remission in IBD patients treated with VDZ. With the longitudinal analysis, we also showed that sMAdCAM-1 was statistically higher before induction of VDZ than during VDZ maintenance therapy, and that its decrease was more pronounced in patients who were in clinical remission during the follow-up.
MAdCAM-1 is overexpressed on gut endothelium in active IBD and is upregulated by TNFα.
14 Elevated levels of sMAdCAM-1 mirror the higher expression of MAdCAM-1. The decrease of sMAdCAM-1 during VDZ therapy argues for its downregulation under VDZ, as previously demonstrated by blocking TNFα and lymphotoxin-β receptor activation.
14, 23 We also showed that pharmacokinetics combining undetectable sMAdCAM-1 and VTL > 19 µg/ mL were independently associated with clinical remission, and this combination was a favorable pharmacokinetic profile with a PPV of 95%. In a recent Phase II placebo-controlled trial evaluating an anti-MAdCAM-1 antibody in UC patients [TURANDOT study], 16 sMAdCAM-1 concentration was measured at baseline and Week 12.
A decrease in sMAdCAM-1 concentration was shown in active treatment, but not under placebo, hence supporting our hypothesis and the growing interest in this biomarker in this setting. Moreover, in the longitudinal analysis, high concentrations of RA before VDZ were predictive of VDZ efficacy, probably because of its ability to induce higher expression of α4β7 integrin on lymphocyte surfaces, as previously described in patients with human immunodeficiency virus. 24 The situation is similar in patients treated with anti-TNFα in whom the response rates to anti-TNF therapy are higher in patients with high numbers of membrane-bound TNF. 25 Indeed, RA is a key physiological factor involved in the induction of α4β7 integrin on lymphocyte surfaces, which is targeted by VDZ. 18, 26, 27 It has also been reported that CD14 + macrophages from the intestinal mucosa of patients with CD are capable of generating RA, which might increase the inflammatory phenotype of these cells. 28 During maintenance therapy, a VTL > 19 µg/mL was associated on multivariate analysis with clinical remission, which agreed with previous data from the literature. 9, 10 However, quartile analyses underlined the lack of specificity of VTL for the diagnosis of clinical remission. Measurement of albumin in blood was not performed in our study, but in contrast to anti-TNF, the impact of serum albumin levels on VTL remains unclear. 29, 30 The median weight of the included patients was 63 kg [range 50-88], and it was not associated with clinical response on univariate analysis. This could be due to the absence in our cohort of patients with 'extreme weight' [>120 kg], since overweight has been identified as a potential clinically important predictor of increased clearance of VDZ. 30 Our study has some limitations. The number of included patients was rather low, which precluded meaningful analyses of subgroups, in particular for quartile analyses, evaluation of treatment optimization, and difference between CD and UC. Likewise, the potential diagnostic value of low RA concentrations for clinical remission could not be assessed from our study due to its lack of statistical power. The short duration of maintenance therapy and the retrospective nature of the study could also be pointed out as limits. However, the included patients had a clinical assessment of the disease activity reported prospectively, with objective parameters such as fCal and endoscopic evaluation at the same time decreasing this limitation. Management of patients was based on these clinical scores and independent of the results of VTL, sMAdCAM-1, and RA concentrations. Our work should be considered as a proof-of-concept study, and the analyzed biomarkers can be easily measured in the future with high reproducibility and feasibility in clinical practice. In an ongoing prospective study, we are measuring sMAdCAM-1 and RA concentrations in order to assess their predictive value for clinical remission during VDZ therapy.
Awaiting further studies, we can only propose with caution the following strategy. Before starting VDZ therapy, RA concentrations should be measured to help decision-making during the followup. Pharmacokinetics combining values of VTL and sMAdCAM-1 should be used if there is a loss of response during maintenance therapy: in the case of a 'favorable' pharmacokinetic profile [undetectable sMAdCAM-1 and a VTL of >19 µg/mL], the switch to therapeutic class other than VDZ should be recommended. Optimization of treatment should be proposed if sMAdCAM-1 is detectable with low VTL. With other pharmacokinetic profiles [VTL > 19 µg/mL and detectable sMAdCAM-1; VTL ≤ 19 µg/mL and undetectable sMAd-CAM-1], it appears necessary to assess the probability of clinical remission under VDZ: if RA before induction therapy is <1.86 ng/ mL, this probability should be low, and a switch of therapeutic class should be proposed. In contrast, if RA is >1.86 ng/mL, optimization of VDZ therapy should be tried. At the moment, this algorithm is to be used with caution, and further studies are needed to improve its level of evidence.
In conclusion, undetectable sMAdCAM-1 appears strongly associated with clinical remission during VDZ maintenance therapy in IBD patients. sMAdCAM-1 is actually an inflammatory surrogate marker that probably does not interfere with the effectiveness of VDZ. We observe that it is higher in responder patients before treatment, because the expression of sMAdCAM-1 is also correlated with the expression of MAdCAM-1 on vessels. This indicates that the inflammatory process involved is dependent on lymphocyte migration via this system. This surrogate marker [sMAdCAM-1], however, is unique in predicting the response to VDZ, which is not the case for CRP or fCal. During maintenance therapy, the rate of sMAdCAM-1 falls in responder patients, because it ultimately reflects the decrease in inflammation in these patients. This decreased expression of MAdCAM-1 has already been observed in patients receiving anti-TNF induction therapy.
14 Both these induction and maintenance observations suggest that sMAdCAM-1 may bind to α4β7 without inhibiting VDZ uptake.
In addition, a pharmacokinetic profile combining undetectable sMAdCAM-1 with high VTL might be potentially be an indicator for TDM. Concentrations of RA before induction are predictive of clinical remission under VDZ therapy. Our findings need to be 
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Vedolizumab trough levels (μg/mL) confirmed in further prospective studies that allow the elaboration of a decisional algorithm. Our data also show that the pharmacokinetics of VDZ are quite complicated and involve different actors/ molecules. A mechanistic study of the different molecules involved in the efficacy of VDZ seems to be crucial in order to optimize this treatment in IBD patients.
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